Registrations open for SOSV’s First Sustainable Industry Tech Matchup. Learn More.

Melanie Matheu

Dr. Matheu co-founded Prellis Biologics in October 2016 to address the unsolved biomedical challenge of rapid 3D printing of large, vascularized tissues. She is a specialist in two-photon imaging of the immune system, and developed Prellis’ platform technology, a combination of her multi-disciplinary experience in two-photon laser microscopy, cell biology, physiology, and biophysics. While ascribing to a form-begets-function mandate, Dr. Matheu and her team are reverse-engineering native tissue development. Through this process, she believes that it is possible to jump-start large-format vascularized tissue printing for pharmaceutical testing, rapid development of high affinity human antibodies, and production of organs for transplant applications. Melanie acted as CEO at Prellis until 2021, when she brought in Dr. Michael Nohaile as CEO. She has stayed on as Co-founder, CSO, and board member.

Did you know?